[Gene polymorphisms]
- PMID: 21115419
- DOI: 10.1684/bdc.2010.1203
[Gene polymorphisms]
Abstract
Cancers can be considered as gene diseases. A number of mechanisms leading to cancer have been identified through the discovery of structural alterations of genes called 'oncogenes' and 'tumour suppressor genes'. Somatic and germinal mutations are rare but play a determinant role in the emergence of cancer, while common and frequent variations (polymorphisms) play a role in cancer susceptibility and in the effects of anticancer drugs (efficacy and toxicity). After a general overview on the structural and functional organisation of the human genome, we present here some of the techniques aimed at the identification of structural DNA variations. We present afterwards some examples of the role that play polymorphic constitutive variations of the genome in the occurrence of cancer (molecular epidemiology) and the activity of anticancer drugs (pharmacogenetics).
Similar articles
-
[Towards an inventory of oncogenic mutations in cancer].Bull Cancer. 2010 Nov;97(11):1223-9. doi: 10.1684/bdc.2010.1200. Bull Cancer. 2010. PMID: 21059490 Review. French.
-
On the use of pharmacogenetics in cancer treatment and clinical trials.Eur J Cancer. 2014 Oct;50(15):2532-43. doi: 10.1016/j.ejca.2014.07.013. Epub 2014 Aug 4. Eur J Cancer. 2014. PMID: 25103456 Review.
-
MicroRNAs.Cancer J. 2008 Jan-Feb;14(1):1-6. doi: 10.1097/PPO.0b013e318164145e. Cancer J. 2008. PMID: 18303474 Review.
-
SomInaClust: detection of cancer genes based on somatic mutation patterns of inactivation and clustering.BMC Bioinformatics. 2015 Apr 23;16:125. doi: 10.1186/s12859-015-0555-7. BMC Bioinformatics. 2015. PMID: 25903787 Free PMC article.
-
Oncogenes and tumor suppressor genes.Hosp Pract (Off Ed). 1993 Jun 15;28(6):145-8, 153-6, 161. doi: 10.1080/21548331.1993.11442812. Hosp Pract (Off Ed). 1993. PMID: 8509476 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources